A new series of alkylating agents, 2-chloroethylnitrososulfamides (CENS), were developed on the model of 2-chloroethylnitrosoureas. Starting from chlorosulfonyl isocyanate, a four-step synthesis (carbamoylation-sulfamoylation, Mitsunobu alkylation, deprotection, and nitrosation) gives the title compounds in a 47-58% overall yield. The selection of the nitrosation site can be directed through an alternative route. The pharmacological evaluation shows a significant oncostatic activity towards both A549 and MCF7 cell lines.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0968-0896(96)00118-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia: A Randomized Controlled Trial.
J Clin Psychiatry
January 2025
Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York, and Department of Psychiatry, New York University School of Medicine, New York, New York.
There are few established treatments for negative symptoms in schizophrenia, which persist in many patients after positive symptoms are reduced. Oxidative stress, inflammation, and epigenetic modifications involving histone deacetylase (HDAC) have been implicated in the pathophysiology of schizophrenia. Sulforaphane has antioxidant properties and is an HDAC inhibitor.
View Article and Find Full Text PDFAn evaluation of clonal relationship by PFGE method in Acinetobacter baumannii isolates, examining integron presence and antibiotic resistance.
J Infect Dev Ctries
December 2024
Department of Medical Microbiology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
Introduction: This study aims to investigate the presence of class 1, 2, and 3 integrons in Acinetobacter baumannii isolates, evaluate the relationship between integrons and antibiotic resistance and determine the clonal relationship between isolates by PFGE method.
Methodology: A total of 188 A. baumannii strains between February 2020 and March 2023 were included in the study.
A cross-sectional study on the prevalence of multidrug-resistant clinical isolates of Proteus species in Northern Iran.
J Infect Dev Ctries
December 2024
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Introduction: Multidrug-resistant (MDR) bacteria like Proteus species have led to more prolonged hospitalizations, fewer care choices, higher treatment costs, and even death. The present study aims to evaluate the prevalence of MDR Proteus species in clinical samples and to suggest the best therapeutic options for the MDR Proteus species.
Methodology: Clinical samples were collected randomly from five hospitals in Golestan Province, Iran, from February 2017 to July 2019.
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer.
Oncologist
January 2025
Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON M5G 2M9, Canada.
Background: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. This study evaluated JNJ-70218902 (JNJ-902), a T-cell redirector targeting transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains 2 (TMEFF2) and cluster of differentiation 3, in mCRPC.
Patients And Methods: Patients who had measurable/evaluable mCRPC after at least one novel androgen receptor-targeted therapy or chemotherapy were eligible.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!